礼来单抗/多肽药物组合达3期临床主要终点礼来(Eli Lilly and Company)今日宣布,TOGETHER-PsO临床3b期研究取得积极顶线结果。该研究评估了Taltz(ixekizumab)联合Zepbound(tirzepatide)相较Taltz单药治疗,在中重度斑块状银屑病合并肥胖或超重(且伴至少一种体重相关合并症)成人患者中的疗效差异。Taltz是一种单克隆抗体,可选择性结合...
Source Link礼来单抗/多肽药物组合达3期临床主要终点礼来(Eli Lilly and Company)今日宣布,TOGETHER-PsO临床3b期研究取得积极顶线结果。该研究评估了Taltz(ixekizumab)联合Zepbound(tirzepatide)相较Taltz单药治疗,在中重度斑块状银屑病合并肥胖或超重(且伴至少一种体重相关合并症)成人患者中的疗效差异。Taltz是一种单克隆抗体,可选择性结合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.